Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-8-29
|
| pubmed:abstractText |
24 patients with recurrent (group 1) or primary (group 2) bladder cancer (ta/t1 G2) were given 50.000.000 U.I. of beta interferon intravesically after TUR of the neoplasm. In group 1 recurrence rate (rr) was 100% in the period before INF and 83% after INF treatment (follow-up 15-24 months, median 19.8) (p = ns). In group 2 rr was 25% in a 24 months, median 19.8) (p = ns). In group 2 rr was 25% in a 24 months follow-up period; if compared to the rr of a historical control group treated by only a TUR (38.2%) there was a statistically significant difference (p less than 0.01). Tolerability of the drug was excellent.
|
| pubmed:language |
ita
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1120-8538
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
63
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
135-40
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1830405-Administration, Intravesical,
pubmed-meshheading:1830405-Female,
pubmed-meshheading:1830405-Humans,
pubmed-meshheading:1830405-Interferon Type I,
pubmed-meshheading:1830405-Male,
pubmed-meshheading:1830405-Middle Aged,
pubmed-meshheading:1830405-Neoplasm Recurrence, Local,
pubmed-meshheading:1830405-Urinary Bladder Neoplasms
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
[Intravesical chemoprophylaxis with beta-interferon in superficial carcinoma of the bladder].
|
| pubmed:affiliation |
Clinica Urologica, Università di Cagliari.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|